The hepatitis C virus is a leading cause of liver disease and a major healthcare concern with over 71 million people chronically infected worldwide resulting in 399,000 deaths per year.1 Due to the high rate of asymptomatic infections, clinical diagnosis is difficult and screening assays are of major importance.2
Chronic HCV infection may lead to cirrhosis and hepatocellular carcinoma, therefore, early detection of antibodies to HCV is the first step in the management of chronic hepatitis and in the selection of patients needing treatment.3
Elecsys® Anti-HCV II is used to demonstrate the presence of antibodies against HCV during acute and chronic infection, and after a resolved infection.
